Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The table above records the past week’s major catalyst events that occurred in the late-stage pipeline during the past week (see table for relevant dates), created using Citeline’s Biomedtracker.
The table lists drugs at Phase II or above for which an important catalyst was recorded during the week, according...
Create an account to read this article
Already a subscriber?
The company believes its novel treatment NASP could drive use in a category where medication is underutilized.
The nasal spray formulation of bumetanide was approved by the US FDA for edema associated with congestive heart failure and hepatic and renal disease.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
